Saturday 17 October 2026
Export MEDS’s income statement to Excel — free account
DataMeds AI, Inc
MEDS Healthcare Pharmaceutical Retailers
DataMeds AI, Inc’s revenue for fiscal 2025 (year ended December 2025) was $23.3 million, up 28.7% from fiscal 2024. In the quarter to June 2026, revenue fell 77.2%, EPS fell 29.6%, free cash flow fell 41.9% and total debt fell 15.4%, each against the same quarter a year earlier.
2.63
0.22
−7.72%
Follow MEDS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 16.80 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 352.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 31 | 31 | 7 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.58 | 3.33 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 18 | 23 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 9.75 | (27.54) | |||||
| EBT | — | — | — | — | — | — | — | (3) | (7) | (101) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | (37.82) | (433.95) | |||||
| Net income | — | — | — | — | — | — | — | (3) | (7) | (101) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 1 | 16 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 19.18 | 16.44 | ||||
| Earnings | — | — | — | — | — | — | — | (3.24) | (7.50) | (71.50) | |||||
| Cash flow | — | — | — | — | — | — | — | (0.39) | (1.30) | (7.65) | |||||
| Capex | — | — | — | — | — | — | — | 0.00 | (0.40) | (0.62) | |||||
| Free cash flow | — | — | — | — | — | — | — | (0.39) | (1.70) | (8.27) | |||||
| Book value | — | — | — | — | — | — | — | (3.24) | 7.13 | (8.77) | |||||
| Shares, m | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 1.22 | |||||
| P/B | — | — | — | — | — | — | — | — | 26.73 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 2.22 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (165.21) | (4.42) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 0 | (1) | (11) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | |||||
| Free cash flow | — | — | — | — | — | — | — | 0 | (2) | (12) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (3) | (23) | (27) | ||||
| Total debt | — | — | — | — | — | — | — | 0 | 23 | 23 | |||||
| Net debt | — | — | — | — | — | — | — | 0 | 22 | 23 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (3) | 7 | (12) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (23.78) | (230.71) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (13.20) | (532.81) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (357.65) | 3,545.16 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
DataMeds AI, Inc vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HITI High Tide Inc. | $228.2M | — (loss-making) | 92.0× | +30.72% (above 0%: growing) | +800.00% (above 0%: growing) | −7.91% (below 0%: shrinking) | 26.53% | 4.38% | Compare |
| PETS PetMed Express, Inc. | $26.4M | — (loss-making) | 24.0× | −19.86% (below 0%: shrinking) | n/m | +38.60% (above 0%: growing) | 27.63% | (15.19%) | Compare |
| MEDS DataMeds AI, Inc | $12.8M | — (loss-making) | — | −77.15% (below 0%: shrinking) | n/m | −41.85% (below 0%: shrinking) | 10.24% | (412.67%) | |
| SCNX Scienture Holdings, Inc. | $5.6M | — (loss-making) | — (loss-making) | +3,235.92% (above 0%: growing) | n/m | −53.98% (below 0%: shrinking) | 97.73% | (785.71%) | Compare |
| POM Pomdoctor Limited - Sponsored ADR | $5.0M | — | — | — | — | — | — | — | Compare |
| RDGT Ridgetech Inc. | $3.0M | — (loss-making) | — (loss-making) | +113.14% (above 0%: growing) | n/m | +4,848.31% (above 0%: growing) | 22.81% | 0.00% | Compare |
| MDVLQ MedAvail Holdings, Inc. | $2.9M | — (loss-making) | — (loss-making) | −25.41% (below 0%: shrinking) | n/m | +66.32% (above 0%: growing) | 43.95% | (1,099.75%) | Compare |
| BIMI BIMI Holdings Inc. | $170.0K | — (loss-making) | — | −48.85% (below 0%: shrinking) | n/m | +28.06% (above 0%: growing) | 4.57% | (124.83%) | Compare |
| Median of peers | $5.0M | — | — | +5.43% | — | +33.33% | 27.08% | (70.01%) |
DataMeds AI, Inc (MEDS) key facts
- Strength: DataMeds AI, Inc’s revenue for fiscal 2025 (year ended December 2025) was $23.3 million, up 28.7% from fiscal 2024.
- DataMeds AI, Inc (MEDS) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MEDS traded at $2.63, a market capitalization of $12.8 million.
- DataMeds AI, Inc does not currently pay a dividend.
- Return on equity was 3,545.2% and debt-to-equity -1.01.
- Its Altman Z-score is −15.16 (distress zone) for fiscal 2025.